![Page 1: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/1.jpg)
Targeted Lung Denervation (TLD) in moderate to severe COPD Patients
Arschang Valipour, MD (Study Principal Investigator)Department of Respiratory and Critical Care MedicineO7o-Wagner-Spital, Vienna, Austria06 Sept 2016
IPS-I/II, AIRFLOW-1, and AIRFLOW-2 Trials
![Page 2: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/2.jpg)
• Safety • Feasibility • Dose Ranging
IPS-I / IPS-II
Optimization
• Safety • Efficacy
Pivotal
Feasibility
Key Areas to Optimize • Dose • Procedure • Protocol
TLD COPD Research Program
Generation 1 Device
Generation 2 Device
![Page 3: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/3.jpg)
Overview IPS StudiesSummary IPS-I (NCT# 01483534) IPS-II (NCT# 01716598)
DesignMulticenter study with
staged treatment of right & left lungs
Multicenter study with bilateral treatment of
right & left lungs
ObjectiveAssess safety and
feasibility of TLD over 2 procedures
Assess safety and feasibility of TLD during
1 procedure
Endpoints• Technical feasibility• Freedom from worsening of COPD• Physiological changes (PFT, exercise, QOL)
Patient #n=22
(12 at 20 waYs; 10 at 15 waYs)
n=15 (15 at 15 waYs)
Follow-upDays: 3 and 10
Months: 1, 3, 6 and 9Years: 1, 2 and 3
![Page 4: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/4.jpg)
Available Subjects Over Time (re-consented for longer term follow-up at 1-year, if willing)
IPS-I (n=22)
20
19
15
IPS-II (n=15)
15
10
9
1 Year
2 Years
3 Years
![Page 5: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/5.jpg)
16
1
6
8
4
1
6
1
6MONTHS 1YEAR 2YEARS 3YEARS
ALL
IPS-I IPS-II
IPS-I/II Serious Adverse Events Through 3 Years*
*IPS-I required 2 bronchoscopies 30 days apart
No long-term airway effects reported
-COPD Exac.x3 -gastroenteritis -pancreatic cancer -Pneumonia
-COPD Exac.x3 -hemoptysis -motorcycle accident -stroke
-COPD Exac. x6 -COPD death -pancreatic death
-stroke 11
1
4
7
1 1
3
0
6MONTHS 1YEAR 2YEARS 3YEARS
RESPIRATORYRELATED
IPS-I IPS-II
![Page 6: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/6.jpg)
IPS-I Long-term Airway Safety
90 Day
1 Year
Baseline
![Page 7: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/7.jpg)
IPS-I: Efficacy is Dose Dependent*
*Slebos, et. al., Thorax May 2015
Stronger benefit seen at higher dose
![Page 8: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/8.jpg)
IPS-I: Potential Additive Effect*
*Koegelenberg et al., Respiration June 2016
TLD + drug may exceed any other bronchodilator combination therapy
![Page 9: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/9.jpg)
IPS Conclusions
• Long-term safety established with no negative airway effects reported out to 3 years.
• Clear trend toward beYer efficacy at higher dose• Efficacy demonstrated by:– TLD alone– TLD + drug– Efficacy sustained over time with TLD
![Page 10: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/10.jpg)
Dose and procedural optimization study with generation 2 system
(NCT#02058459)
![Page 11: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/11.jpg)
AIRFLOW-1 Study Overview Energy Level
GroupN=30
3 month optimal power selection based on safety and
efficacyanalysis
ConfirmationGroupN=16
DesignMulticenter, randomized
study assessing two energy levels
Multicenter registry assessing optimal energy
level with procedural enhancements
Objective Assess safety and establish optimal energy level
Assess safety and impact of procedural enhancements
at optimal dose
Primary Endpoint
Rate of airway effects requiring intervention
through 3 months(3 month airway inspection)
Rate and frequency of AEs at
1 month compared to Randomized group.
Energy Level(s)
Low (29 WaYs) and
High (32 WaYs)High (32 WaYs)
![Page 12: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/12.jpg)
AIRFLOW-1 Collaborating Sites AustriaOYo Wagner Spital, Vienna. A. Valipour AKH Allgemeines Krankenhaus, Linz. B. Lamprech
BelgiumAZ Leuven, Leuven. W. Janssens CHU Saint Pierre, Brussels. V. Ninane
FranceCHU de Grenoble. C. Pison CHU de Lille. T. Perez
CHU de Reims. G. Deslee CHU de Strasbourg. R. Kessler
CHU de Paris. A. Marceau
GermanyCharite-Universitatsmedizin, Berlin. R. Hübner Asklepios-Fachkliniken, Gauting. W. Gesierich
Thoraxklinik, Heidelberg. F. Herth
NetherlandsUniversity Medical Centre Groningen. D. Slebos
United KingdomRoyal Brompton, London. P. Shah
![Page 13: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/13.jpg)
AIRFLOW-1 Key Inclusion/ExclusionInclusion:! FEV1 30% to 60% ! FEV1/FVC <70%! mMRC grade ≥2 or CAT score ≥10 ! Relative change in FEV1 and/or FVC of >12% and 200 mL during
ipratropium reversibility testing! Non smoking ≥4 months
Exclusion:• <6 weeks since COPD exacerbation or active respiratory infection • PaO2 ≤ 7.3 kPa (55 mm Hg) or PaCO2 > 8.0 kPa (60 mm Hg)• Pulmonary nodule requiring surgery, radiation and or/chemotherapy• Previous abdominal surgical procedures• Elevated baseline gastric questionnaire score
![Page 14: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/14.jpg)
AIRFLOW-1 Conclusions
• AIRFLOW-1 confirms and builds on IPS studies• Advancements in procedural technique significantly
improved safety profile– Enhanced airway protection– Esophageal management
• Multiple efficacy measures suggest effect of TLD with
generation 2 system• Early evidence of both sustained benefit of TLD alone and
additive effect of TLD + drug• Confirmation Group data available in 2017
![Page 15: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/15.jpg)
First randomized sham control study for TLD
(NCT#02058459)
![Page 16: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/16.jpg)
AIRFLOW-2 Study Overview
Design Multicenter, randomized sham-controlled study
Objective Assess safety and feasibility outcomes between TLD vs. sham-control
Primary Endpoint Rate of respiratory related adverse events between 3 and 6.5 months
Patient # n=80 (1:1 randomization)
Follow-upWeeks: 1
Months: 1, 3, 6*, 9 Years: 1*, 1.5, 2, 2.5, 3
Status Enrolling
*on and off drug assessment time-point
![Page 17: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/17.jpg)
AIRFLOW-2 Key Inclusion/ExclusionMajor Inclusion:! FEV1 30% to 60% ! FEV1/FVC <70%! mMRC grade ≥2 or CAT score ≥10 ! Non smoking ≥2 months
Major Exclusion:• <6 weeks since COPD exacerbation or active respiratory infection • PaO2 ≤ 7.3 kPa (55 mm Hg) or PaCO2 > 8.0 kPa (60 mm Hg)• Pulmonary nodule requiring surgery, radiation and or/chemotherapy• Elevated baseline gastric questionnaire score
![Page 18: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/18.jpg)
AIRFLOW-2 Inflammatory Sub-study
• Goal: understand anti-inflammatory effects of TLD– 40 subject to participate (20 test, 20 sham)– Expand on results from earlier IPS-I Study
Kistemaker et al., Eur Respir J (2015)
![Page 19: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/19.jpg)
AIRFLOW-2 Collaborating Sites Austria
OYo Wagner Spital, Vienna. A. Valipour AKH Allgemeines Krankenhaus, Linz. B. Lamprech
France
CHU de Grenoble. C. Pison CHU de Lille. T. Perez
CHU de Reims. G. Deslee CHU de Strasbourg. R. Kessler
CHU de Paris. A. Marceau
Germany
Charite-Universitatsmedizin, Berlin. R. Hübner Asklepios-Fachkliniken, Gauting. W. Gesierich
Thoraxklinik, Heidelberg. F. Herth Ruhrlandklinik, Essen. K. Darwiche
Klinikverbund, Kempten. C. Schumann
Netherlands
University Medical Centre Groningen. D. Slebos Academisch Medisch Centrum. P. Bonta
United Kingdom
Royal Brompton, London. P. Shah Queen Elizabeth University Hospital, Glasgow S. Bicknell
![Page 20: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/20.jpg)
www.airflowtrial.com
![Page 21: Targeted Lung Denervation (TLD ) in moderate to severe ... · Exclusion: •](https://reader034.vdocument.in/reader034/viewer/2022050205/5f583f1b27b816487a75ddbc/html5/thumbnails/21.jpg)
Thank you